Genomics

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Cellular assays #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Organic chemistry #PCR #Protein chemistry / Proteomics #Screening #Sequencing #Target validation

Synthetic approaches to rational drug design – A changing landscape

Synthetic approaches to rational drug design - A changing landscape By Dr Shubh Sharma and Dr Carl Spana It is becoming clearer that newer synthetic approaches for rational drug design may hold the promise of taking us closer to industrialising drug discovery while, at the same time, overcoming the bottleneck… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Protein chemistry / Proteomics #Screening #Sequencing #System biology #Systems biology #Therapeutics

The cost and value of three-dimensional protein structure

The cost and value of three-dimensional protein structure By Professor Raymond C. Stevens During the past few years we have seen the cost of protein three-dimensional structure determination begin to converge by protein family type, there has been a commoditisation of high-throughput structure based drug discovery technology components, and the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #Metabolomics #Molecular medicine #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Molecular pathology and the art of drug design

Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #Immunology #Immunology / Virology & Vaccines #Oncology #PCR #Protein chemistry / Proteomics #Regulatory #RNA

Public Relations and the Drug Discovery Industry

Public Relations and the Drug Discovery Industry By Dr Richard Franklin The use of the Public Relations (PR) industry to promote all facets of the pharmaceutical industry is on the increase. We take a brief look at the various uses of PR and the sectors that are being promoted. Public… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Mass spectrometry / NMR #Oncology #PCR #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The Protein Biochip Content Problem

The Protein Biochip Content Problem By Dr Steven Bodovitz The protein biochip industry has a content problem that is not only slowing its development as a whole but possibly the development of the entire proteomics industry. In science, for a problem to have its own name, it needs to be… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

RNA interference – A technology platform for target validation, drug discovery and therapeutic development

RNA interference - A technology platform for target validation, drug discovery and therapeutic development By Dr Krishnarao Appasani In the post genomic era, elucidation of the physiological function of genes has become a major rate-limiting step in the quest to develop 'gene-based-drugs'. As we advance in the 'functional omics' arena… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Immunology #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Organic chemistry #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Functional proteomics in drug discovery

Functional proteomics in drug discovery By Dr Stefan W. Henning and Dr Leodevico L. Ilag The critical bottleneck of the drug discovery process is developing the right drug for the right target. Today proteins represent more than 90% of druggable targets and will most likely remain the single most important… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Pathology #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Target validation #Therapeutics

The role of ZEBRAFISH in drug discovery

The role of ZEBRAFISH in drug discovery By Dr Paul Goldsmith and Roberto Solari The NIH has ranked the Zebrafish as the third most important experimental organism after man, the Sanger Centre is sequencing the genome and many medical researchers are shifting over to it. But will the zebrafish have… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #PCR #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Target validation

TRANSCRIPTOMICS – Realising the promise with a new era of drug discovery and diagnostics

TRANSCRIPTOMICS - Realising the promise with a new era of drug discovery and diagnostics By Dr Bruce Seligmann The advent of modern genomics has provided new ways to link targets to diseases and validate these targets. The result is the potential for a new era of drug discovery transcriptomics or… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #Organic chemistry #RNA #Screening

Compound Management comes of age

Compound Management comes of age By Ian Yates The changing role of compound management in recent years has seen an often under-valued and under-resourced function being recognised as a key part of the drug discovery process. This article examines the challenges faced by compound management teams and, at a high… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Biochemistry #Biomarkers #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High throughput screening #In Silico Biology #Lead discovery #Microbiology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Target validation #Toxicology

Balancing Quantity and Quality in Drug Discovery

Balancing Quantity and Quality in Drug Discovery By Eva-Lotta Allan There is a need to innovate in order to stay ahead, a need to maximise the value of the R&D engine by increasing the flow of novel drug candidates and yet, reduce the time to market. Does access to more… Read More

#Archive

#Animal models #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Immunology #Lead discovery #Oncology #Pharmokinetics #Preclinical #RNA #Sequencing #Stem cells #System biology #Systems biology

Second-Generation Protein Drugs

Second-Generation Protein Drugs By Dr Jeffrey C.Way The first biotech revolution was catalysed in the late 1970s with the development of recombinant DNA technology. This revolution generated numerous billion-dollar protein drugs such as erythropoietin and the interferons. Now that the patents on these drugs are expiring, will second generation proteins,… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Microfluidics #PCR #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Secondary Screening Workstations: Compact turnkey solutions that work

Secondary Screening Workstations - The emergence of compact turnkey solutions that work By Dr John Comley With the launch of new workstations focused on secondary screening applications not only are we witnessing the shrinkage of laboratory automation but we are seeing the emergence of true walk-away solutions, ie set up… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Microbiology #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Protein Arrays for Assessment of Target Selectivity

Protein Arrays for Assessment of Target Selectivity By Professor Ian Humphery-Smith, Dr Erik Wischerhoff and Dr Ryuji Hashimoto Transforming knowledge of the human genome into a lead optimisation tool. Genomics activity has been criticised for having elucidated a plethora of potentially interesting drug targets, each awaiting further validation, but having… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Molecular medicine #Organic chemistry #PCR #Pharmacology #Precision medicine #RNA #Screening #Target validation #Therapeutics #Toxicology

Better drugs by MICROARRAY

Better drugs by MICROARRAY By Dr Mark Schena Microarray analysis allows the elucidation of biological processes and pathways on a genomic scale. This revolutionary technology promises an unprecedented view of drug action and side reaction, the ability to identify drug targets and optimise lead compounds, the capacity to predict patient… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #System biology #Systems biology #Target validation

The New Blockbuster Drugs – Healthcare packages for particular disease pathologies

The New Blockbuster Drugs - Healthcare packages for particular disease pathologies By Dr Nick Davies and Dr Steve Arlington With the cost of bringing a new drug to market now exceeding $800 million there is no doubt that the pharmaceutical industry has to fundamentally address the way in which it… Read More

#Archive